Free tool
Drugs in development
Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations
Drugs in development
3,685
Not FDA-approved
In Phase 3
1,424
Highest phase reached
Matching your filters
287
287 drugs in development
Names, sponsors and conditions come from the trial records. Click a drug for its trials.
- Supportive care measuresPhase 36 trials
Merck & Co. · Esophageal Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
- VebreltinibPLB1001Phase 36 trials
Avistone Biotechnology Co., Ltd. · Non-Small-Cell Lung Cancer, Glioblastoma, Non-Small Cell Lung Cancer
- VisugromabCTL-002, Visugromab RDEPhase 36 trials
CatalYm GmbH · Adult Solid Tumor, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Unresectable or Metastatic Hepatocellular Carcinoma
- aglatimagene besadenovecCAN-2409, AdV-tkPhase 35 trials
Candel Therapeutics, Inc. · Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
- almonertinibPhase 35 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced Solid Tumors, Relapsed or Advanced Non-small Cell Lung Cancer
- CeralasertibAZD6738Phase 35 trials
AstraZeneca · Melanoma, Advanced or Metastatic NSCLC, Non-Small Cell Lung Cancer
- GlumetinibSCC244Phase 35 trials
Shanghai JMT-Bio Inc. · Non-Small Cell Lung Cancer, Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression, C-Met Exon 14 Mutation
- HRS-7058Phase 35 trials
Shandong Suncadia Medicine Co., Ltd. · KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment, Solid Tumors, Pancreatic Cancer
- ONC-392Gotistobart, BNT316Phase 35 trials
OncoC4, Inc. · Non Small Cell Lung Cancer, Ovarian Cancer, Advanced Solid Tumor
- PyrotinibPhase 35 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Solid Tumors, Non-small Cell Lung Cancer, HER2-expressing Advanced Solid Tumors
- AL8326Phase 34 trials
Advenchen Pharmaceuticals, LLC. · Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
- AtebimetinibIMM-1-104, Group APhase 34 trials
Immuneering Corporation · Pancreatic Adenocarcinoma, Advanced Solid Tumor, Malignant Melanoma (Cutaneous)
- FirmonertinibAST2818Phase 34 trials
Allist Pharmaceuticals, Inc. · Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer
- GimistotugBGB-A445Phase 34 trials
BeOne Medicines (BeiGene) · Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma
- H2 receptor antagonistPhase 34 trials
Merck & Co. · Lung Neoplasm Malignant, Esophageal Squamous Cell Carcinoma, Ovarian Cancer
- HB0025Phase 34 trials
Shanghai Huaota Biopharmaceutical Co., Ltd. · First-line pMMR Endometrial Cancer, Non Squamous Non-small Cell Lung Cancer, TNBC
- HLX07Phase 34 trials
Shanghai Henlius Biotech · Colon Cancer Adenocarcinoma, Squamous NSCLC, Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
- JSKN016Phase 34 trials
Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Triple Negative Breast Cancer, Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer
- JSKN033Phase 34 trials
Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Cervical Cancer, Recurrent or Metastatic Cervical Cancer, Advanced Malignant Tumors
- KL-A167Phase 34 trials
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma, Recurrent or Metastatic
- LivmoniplimabABBV-151Phase 34 trials
AbbVie · Hepatocellular Carcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer
- MonalizumabIPH2201Phase 34 trials
AstraZeneca · Non-small Cell Lung Cancer, Advanced Solid Tumors, Squamous Cell Carcinoma of the Head and Neck
- NavlimetostatBMS-986504, MRTX1719Phase 34 trials
Bristol Myers Squibb · Pancreatic Ductal Adenocarcinoma, Metastatic Non-small Cell Lung Cancer With MTAP Deletion, Solid Tumors
- zipalertinibTAS6417, CLN-081Phase 34 trials
Taiho Oncology, Inc. · Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations, Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
- zoldonrasibPhase 34 trials
Revolution Medicines, Inc. · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC
- AMT-116Phase 33 trials
Multitude Therapeutics Inc. · Advanced Solid Tumors, Advanced Non-small Cell Lung Cancer (NSCLC), NSCLC (Advanced Non-small Cell Lung Cancer)
- BelrestotugEOS884448, GSK4428859APhase 33 trials
GSK · Lung Cancer, Non-Small Cell, Neoplasms, Head and Neck
- BGB-15025Phase 33 trials
BeOne Medicines (BeiGene) · Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Advanced Malignancies
- BGB-B2033Phase 33 trials
BeOne Medicines (BeiGene) · Liver Cancer, Hepatocellular Carcinoma, Hepatocellular Cancer
- EIK1001Phase 33 trials
Eikon Therapeutics · Advanced Melanoma, NSCLC, Non Small Cell Lung Cancer (Squamous or Non Squamous)
- H1 receptor antagonistPhase 33 trials
Merck & Co. · Lung Neoplasm Malignant, Ovarian Cancer, Fallopian Tube Cancer
- IO102-IO103Phase 33 trials
IO Biotech · Metastatic Melanoma, Unresectable Melanoma, Melanoma
- LimertinibPhase 33 trials
Jiangsu Aosaikang Pharmaceutical Co., Ltd. · EGFR Activating Mutation, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), MET Positive
- Olvi-Vecolvimulogene nanivacirepvec, GL-ONCPhase 33 trials
Genelux Corporation · Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer
- QuemliclustatPhase 33 trials
Arcus Biosciences, Inc. · Metastatic Pancreatic Ductal Adenocarcinoma, Advanced Non-Small Cell Lung Cancer, Gastrointestinal Tract Malignancies
- Sigvotatug VedotinSGN-B6A, PF-08046047Phase 33 trials
Pfizer · Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
- ABP 234Phase 32 trials
Amgen · Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC), Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
- ASKC202Phase 32 trials
Jiangsu Aosaikang Pharmaceutical Co., Ltd. · EGFR Activating Mutation, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), MET Positive
- BefotertinibPhase 32 trials
Betta Pharmaceuticals Co., Ltd. · Non-Small Cell Lung Cancer, EGFR Sensitive Mutation, Adjuvant Therapy
- EU-sourced KeytrudaPhase 32 trials
Shanghai Henlius Biotech · Non-Squamous Non-Small Cell Lung Cancer, Non Squamous Non Small Cell Lung Cancer
- JAB-3312Phase 32 trials
Allist Pharmaceuticals, Inc. · KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer
- JYP0322Phase 32 trials
Guangzhou JOYO Pharma Co., Ltd · Non Small Cell Lung Cancer, NSCLC (Advanced Non-small Cell Lung Cancer)
- NeladalkibNVL-655Phase 32 trials
Nuvalent Inc. · Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive, Locally Advanced Solid Tumor
- OBI-821OBI-833Phase 32 trials
OBI Pharma, Inc · Triple Negative Breast Cancer, Non-small Cell Lung Cancer
- OciperlimabBGB-A1217Phase 32 trials
BeOne Medicines (BeiGene) · Non Small Cell Lung Cancer, Advanced Malignancies
- OSE2101Phase 32 trials
OSE Immunotherapeutics · Patients With Non-Small Cell Lung Cancer, Solid Advanced Tumor, Lymphoma
- PF-07248144Phase 32 trials
Pfizer · Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer
- PF-08046054SGN-PDL1VPhase 32 trials
Pfizer · Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma
- Precemtabart tocentecanPrecem-TcT, M9140Phase 32 trials
EMD Serono Research & Development Institute, Inc. · Metastatic Colorectal Cancer, Solid Tumors, Gastric Cancer
- SetidegrasibASP3082Phase 32 trials
Astellas · Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.